Growth and neurodevelopmental status in patients with retinopathy of prematurity treated with intravitreal bevacizumab: a case–control study

Abstract Background The current study aimed to evaluate growth and neurodevelopmental status in patients with retinopathy of prematurity (ROP) treated with intravitreal bevacizumab (IVB). Methods This historical cohort study was conducted on neonates with ROP who were treated with IVB and age and bi...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Majid Abrishami, Hassan Boskabadi, Mojtaba Abrishami, Farid Shekarchian, Majid Khadem-Rezaiyan, Nasser Shoeibi
Formato:	article
Lenguaje:	EN
Publicado:	BMC 2021
Materias:	Retinopathy of prematurity Growth Neurodevelopmental status Bevacizumab Retina Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/0d3a9cf2371a456f83ee93a4d6ca78bc
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:0d3a9cf2371a456f83ee93a4d6ca78bc
record_format	dspace
spelling	oai:doaj.org-article:0d3a9cf2371a456f83ee93a4d6ca78bc2021-11-21T12:29:43ZGrowth and neurodevelopmental status in patients with retinopathy of prematurity treated with intravitreal bevacizumab: a case–control study10.1186/s40942-021-00340-62056-9920https://doaj.org/article/0d3a9cf2371a456f83ee93a4d6ca78bc2021-11-01T00:00:00Zhttps://doi.org/10.1186/s40942-021-00340-6https://doaj.org/toc/2056-9920Abstract Background The current study aimed to evaluate growth and neurodevelopmental status in patients with retinopathy of prematurity (ROP) treated with intravitreal bevacizumab (IVB). Methods This historical cohort study was conducted on neonates with ROP who were treated with IVB and age and birth weight-matched controls who did not need IVB. Apgar score less than five, history of blood transfusion and history of infectious diseases were among exclusion criteria. Indirect ophthalmoscopic examinations were performed till complete retinal vascularization. Growth and neurodevelopmental status were evaluated by Age and Stages Questionnaire (ASQ) at the ages of 6, 12, and 18 months. Developmental milestones were assessed in five areas (gross motor, fine motor, personal-social status, problem-solving, and relationship) and overall issues. Results A total of 34 cases and 36 controls were included in the present study. Birth weight and corrected gestational age were not statistically different between the groups. In a follow-up period of 18 months, bevacizumab was effective as a primary treatment in the treatment of severe cases of ROP. There was no significant difference between the two groups regarding the five areas and overall issues in follow-up intervals (P > 0.05). Conclusions The obtained results did not show any growth and neurodevelopmental differences between treatment-naïve infants and those receiving IVB for the treatment of ROP.Majid AbrishamiHassan BoskabadiMojtaba AbrishamiFarid ShekarchianMajid Khadem-RezaiyanNasser ShoeibiBMCarticleRetinopathy of prematurityGrowthNeurodevelopmental statusBevacizumabRetinaOphthalmologyRE1-994ENInternational Journal of Retina and Vitreous, Vol 7, Iss 1, Pp 1-6 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Retinopathy of prematurity Growth Neurodevelopmental status Bevacizumab Retina Ophthalmology RE1-994
spellingShingle	Retinopathy of prematurity Growth Neurodevelopmental status Bevacizumab Retina Ophthalmology RE1-994 Majid Abrishami Hassan Boskabadi Mojtaba Abrishami Farid Shekarchian Majid Khadem-Rezaiyan Nasser Shoeibi Growth and neurodevelopmental status in patients with retinopathy of prematurity treated with intravitreal bevacizumab: a case–control study
description	Abstract Background The current study aimed to evaluate growth and neurodevelopmental status in patients with retinopathy of prematurity (ROP) treated with intravitreal bevacizumab (IVB). Methods This historical cohort study was conducted on neonates with ROP who were treated with IVB and age and birth weight-matched controls who did not need IVB. Apgar score less than five, history of blood transfusion and history of infectious diseases were among exclusion criteria. Indirect ophthalmoscopic examinations were performed till complete retinal vascularization. Growth and neurodevelopmental status were evaluated by Age and Stages Questionnaire (ASQ) at the ages of 6, 12, and 18 months. Developmental milestones were assessed in five areas (gross motor, fine motor, personal-social status, problem-solving, and relationship) and overall issues. Results A total of 34 cases and 36 controls were included in the present study. Birth weight and corrected gestational age were not statistically different between the groups. In a follow-up period of 18 months, bevacizumab was effective as a primary treatment in the treatment of severe cases of ROP. There was no significant difference between the two groups regarding the five areas and overall issues in follow-up intervals (P > 0.05). Conclusions The obtained results did not show any growth and neurodevelopmental differences between treatment-naïve infants and those receiving IVB for the treatment of ROP.
format	article
author	Majid Abrishami Hassan Boskabadi Mojtaba Abrishami Farid Shekarchian Majid Khadem-Rezaiyan Nasser Shoeibi
author_facet	Majid Abrishami Hassan Boskabadi Mojtaba Abrishami Farid Shekarchian Majid Khadem-Rezaiyan Nasser Shoeibi
author_sort	Majid Abrishami
title	Growth and neurodevelopmental status in patients with retinopathy of prematurity treated with intravitreal bevacizumab: a case–control study
title_short	Growth and neurodevelopmental status in patients with retinopathy of prematurity treated with intravitreal bevacizumab: a case–control study
title_full	Growth and neurodevelopmental status in patients with retinopathy of prematurity treated with intravitreal bevacizumab: a case–control study
title_fullStr	Growth and neurodevelopmental status in patients with retinopathy of prematurity treated with intravitreal bevacizumab: a case–control study
title_full_unstemmed	Growth and neurodevelopmental status in patients with retinopathy of prematurity treated with intravitreal bevacizumab: a case–control study
title_sort	growth and neurodevelopmental status in patients with retinopathy of prematurity treated with intravitreal bevacizumab: a case–control study
publisher	BMC
publishDate	2021
url	https://doaj.org/article/0d3a9cf2371a456f83ee93a4d6ca78bc
work_keys_str_mv	AT majidabrishami growthandneurodevelopmentalstatusinpatientswithretinopathyofprematuritytreatedwithintravitrealbevacizumabacasecontrolstudy AT hassanboskabadi growthandneurodevelopmentalstatusinpatientswithretinopathyofprematuritytreatedwithintravitrealbevacizumabacasecontrolstudy AT mojtabaabrishami growthandneurodevelopmentalstatusinpatientswithretinopathyofprematuritytreatedwithintravitrealbevacizumabacasecontrolstudy AT faridshekarchian growthandneurodevelopmentalstatusinpatientswithretinopathyofprematuritytreatedwithintravitrealbevacizumabacasecontrolstudy AT majidkhademrezaiyan growthandneurodevelopmentalstatusinpatientswithretinopathyofprematuritytreatedwithintravitrealbevacizumabacasecontrolstudy AT nassershoeibi growthandneurodevelopmentalstatusinpatientswithretinopathyofprematuritytreatedwithintravitrealbevacizumabacasecontrolstudy
_version_	1718418927246114816

Growth and neurodevelopmental status in patients with retinopathy of prematurity treated with intravitreal bevacizumab: a case–control study

Ejemplares similares